Multiplexed quantitative proteomics in prostate cancer biomarker development

• Published in: Advances in cancer research Vol. 161; p. 31
• Main Authors: Gao, Yuqian, Kim, Hyeyoon, Kitata, Reta Birhanu, Lin, Tai-Tu, Swensen, Adam C, Shi, Tujin, Liu, Tao
• Format: Journal Article
• Language: English
• Published: United States 2024
• Subjects: Biomarkers, Tumor - analysis; Biomarkers, Tumor - metabolism; Chromatography, Liquid - methods; Humans; Male; Mass Spectrometry - methods; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - metabolism; Proteomics - methods; Risk stratification; Protein biomarker; PRM; DIA; Prostate cancer; Early detection; SRM
• ISSN: 2162-5557; 2162-5557
• DOI: 10.1016/bs.acr.2024.04.003

Prostate cancer (PCa) is the most common non-skin cancer among men in the United States. However, the widely used protein biomarker in PCa, prostate-specific antigen (PSA), while useful for initial detection, its use alone cannot detect aggressive PCa and can lead to overtreatment. This chapter provides an overview of PCa protein biomarker development. It reviews the state-of-the-art liquid chromatography-mass spectrometry-based proteomics technologies for PCa biomarker development, such as enhancing the detection sensitivity of low-abundance proteins through antibody-based or antibody-independent protein/peptide enrichment, enriching post-translational modifications such as glycosylation as well as information-rich extracellular vesicles, and increasing accuracy and throughput using advanced data acquisition methodologies. This chapter also summarizes recent PCa biomarker validation studies that applied those techniques in diverse specimen types, including cell lines, tissues, proximal fluids, urine, and blood, developing novel protein biomarkers for various clinical applications, including early detection and diagnosis, prognosis, and therapeutic intervention of PCa.